Story
Collegium Pharmaceutical Stock Tumbles After Cutting Revenue Forecast

Collegium Pharmaceutical (NASDAQ: COLL) shares fell more than 13% in pre-market trading Tuesday after the company cut its full-year revenue forecast, raising concerns about its growth trajectory. The negative outlook overshadowed second-quarter financial results that beat analyst expectations on profit.
Guidance Cut Overshadows Earnings Beat
While Collegium reported adjusted earnings per share of $1.92, comfortably ahead of the consensus estimate of around $1.72, investors focused on the top-line performance and forward-looking statements. Second-quarter net revenue grew 6.3% year-over-year to $199.9 million but fell short of analyst projections, according to a report from Investing.com.
More significantly, the company trimmed its full-year revenue guidance. The midpoint of the new forecast came in approximately 3.4% below prior Wall Street estimates. For investors, a downward revision to future revenue often outweighs a beat on past earnings, as it can signal deteriorating business fundamentals.
Portfolio Performance Shows Mixed Picture
The revised outlook appears linked to continued challenges in the company's core pain management portfolio, which includes products like BELBUCA and Xtampza ER. This segment, which generated $140.9 million in the quarter, is facing persistent headwinds from generic competition.
AdThere were bright spots in the earnings report that failed to offset the guidance cut. Key growth drivers performed well:
- JORNAY PM: Revenue for the ADHD treatment rose 41% year-over-year to $46.1 million.
- AZSTARYS: The newly acquired asset contributed $12.9 million in its first partial quarter with the company.
Market Reaction
The pre-market drop of 13.2% pushed Collegium's stock price toward its 52-week low, erasing the gains accumulated since the company announced its acquisition of AZSTARYS. The sell-off was company-specific, occurring against a backdrop of a largely flat S&P 500, indicating that the move was a direct reaction to the earnings report and guidance rather than a broader market or sector trend.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.